Introduction
Subjects and methods in general after 3-6months. Azathioprine was added to standard therapy at a dose of 1 mg/kg/day after the first Patients rejection episode.
Plasma prolactin concentrations were measured preoperatThe study design was randomized, prospective, and open. ively, on days 1, 3 and 5 postoperatively, and at monthly The study population consisted of 45 recipients of first intervals thereafter. cadaver kidney transplants, who had <5% preformed cytotoxic HLA antibodies. Patients were randomly assigned by
Laboratory investigations
chart numbers to one of two groups. Details on the study population show a well-balanced distribution of patients Duplicate determinations of circulating prolactin were perfollowing randomization ( Table 1 ) .
formed by an enzyme-linked immunoadsorbent assay Group 1 included 23 patients who received conventional (Boehringer Mannheim, Mannheim, Germany). Plasma immunosuppression with cyclosporin and prednisolone. cyclosporin concentrations were measured by a monoclonal Twenty-two patients were assigned to group 2 with the fluorescence polarization immunoassay (Abott Chicago, following protocol: oral administration of bromocriptine, USA). 5 mg/day until anticoagulant therapy or haemodialysis were stopped, and then intramuscular injection of 100 mg of the long-acting dopamine agonist bromocriptine mesylate Follow-up ( Parlodel LARB, Sandoz, Basel, Switzerland ) monthly, along with standard immunosuppression as in group 1.
After discharge, patients were seen once a week for 1 month, In both groups cyclosporin (Sandoz, Basel, Switzerland) every 14 days thereafter for an additional 4 weeks, and at was administered intravenously (3 mg/kg body-weight per least once a month thereafter. day) for the first 72 h after transplantation followed by oral administration twice daily. True plasma levels were mon-Acute allograft failure and acute allograft rejection itored daily during hospitalization, and during every outpatient visit thereafter, and were maintained between 120 and Acute postoperative allograft failure was defined by the 140 ng/ml during the first postoperative month and between necessity of haemodialysis within the first week after 100 and 120 ng/ml thereafter. Cyclosporin levels and doses engraftment. If allograft function did not improve, a percudid not differ between the two groups throughout the study taneous needle biopsy was performed after 4-6 days and period (Table 2 ) .
every 5-7 days thereafter if necessary. Allograft rejection Prednisolone was started on the day of transplantation at was suspected clinically if serum creatinine concentration a dose of 200 mg/day and tapered by 40 mg/day until a dose rose or urinary volume decreased in the absence of clinical of 20 mg/day was reached. The dose was reduced further to signs of dehydration or elevated cyclosporin levels. In patients with laboratory evidence of cyclosporin toxicity the dose of the drug was reduced and rejection was suspected if allograft treatment. The cumulative prednisolone dose over the 6 months follow-up was 2970.3±85.5 and 2947.5±100. 7 mg respectively.
Results
In each group eight patients experienced a CMV infection, while severe bacterial infections (i.e. pneumoPatient and allograft outcome nia and sepsis) were seen in six of the control group Overall patient survival was 97.7% after 6 months, one and in five of those patients receiving bromocriptine. patient in the control group died of fungal septicaemia 4 months after engraftment. Allograft survival at the Adverse effects end of the 6 months follow-up period was 91%. In the No major complications occurred after bromocriptine control group one patient lost his graft from irreversadministration, and side-effects were minimal, conible rejection after 10 days, as did two patients receiving sisting mainly of dizziness and nausea. Therefore no bromocriptine after 10 and 14 days respectively. In the patient was withdrawn from the study. bromocriptine group one additional patient lost his graft after 5 months. Histologically, chronic allograft rejection was the prominent feature. In the remaining Discussion patients serum creatinine levels did not differ significantly between the two groups throughout the study Acute rejection is an important risk factor for graft period (Table 3 ) .
loss after cadaveric kidney transplantation [16] [17] [18] [19] . Although graft rejections are treated with increasing Serum prolactin concentrations and numbers of allograft success by new drugs, any antirejection therapy is rejection episodes accompanied by negative effects such as adverse drug reactions, hospitalization, and considerable costs. Due Before transplantation prolactin serum concentrations were slightly above the normal range due to renal to its prolactin-suppressing effect the dopamine agonist bromocriptine has long been used in the treatment of insufficiency in both groups (33.0±5.4 and 32.4± 5.7 ng/ml respectively; normal range 2.5-20 ng/ml ). hyperprolactinaemia and its safety has been proven in Bromocriptine mesylate as immunosuppressive drug after kidney transplantation 751 long-term studies over many years. Evidence from in [25, 26] . The fact that in the present study bromocriptine was added to standard cyclosporin therapy without vitro and in vivo studies in animals and men [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] , suggesting that prolactin has immunostimulatory differences in cyclosporin dosage and serum levels in both groups could possibly explain the data: The properties, prompted the present study.
Prolactin receptor, a member of the growth factor potent immunosuppressive effect of cyclosporin in standard dosage alone might not be augmented by receptor superfamily, has been identified on human T-and B-lymphocytes [2 ] . Furthermore prolactin was suppression of prolactin.
In conclusion, suppression of circulating pituitary found to induce IL-2 receptors on splenocytes, hence increasing lymphocyte response to this cytokine [20] , derived prolactin levels with bromocriptine does not improve the immunosuppressive effect of cyclosporin and to enhance PBMC proliferation in response to IL-2 and PHA [21] . In addition, prolactin-translocation at standard dosage nor increase the incidence of infections after first cadaver kidney transplantation. As into the nucleus of T cells is necessary for IL-2-stimulated proliferation of T cells [22] . Furthermore, clinical use of cyclosporin as immunosuppressive agent to prevent graft loss is limited by its dose-related sidedecreased IFN c production was measured in hypoprolactinaemic animals [8 ] and anti-PRL antibodies have effects, the combination of low-dose cyclosporin in addition to the immunosuppressive effect of bromocbeen shown consistently to inhibit mitogen-induced stimulation of human PMNC. Both effects could be riptine-induced prolactin suppression could be an interesting alternative. Further studies will be necessary to restored by the addition of human prolactin [4] . It has also been demonstrated that prolactin antagonizes validate the effectiveness of combining bromocriptine with low-dose cyclosporin in kidney transplantation. competitively the action of cyclosporin A at the receptor level in mixed populations of human peripheral 
